TY - JOUR
T1 - Cutting edge
T2 - Reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide
AU - Daikh, D. I.
AU - Wofsy, D.
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2001/3/1
Y1 - 2001/3/1
N2 - Cyclophosphamide (CTX) prevents progression of nephritis and prolongs survival in (NZB x NZW)F1 (B/W) mice and is used to treat humans with lupus nephritis. To compare the efficacy of CTLA4Ig with CTX and determine whether there is an incremental benefit to combining CTLA4Ig with CTX, we treated B/W mice with CTX, CTLA4Ig, or both agents. In mice with mild renal disease, treatment delayed the onset of proteinuria and prolonged survival in all groups. In mice with advanced renal disease, treatment with both agents reduced proteinuria in 71% of mice, whereas mice treated with either agent alone had no such improvement. Survival was also markedly improved among mice treated with both agents. Thus, combination treatment with CTX and CTLA4Ig is more effective than either agent alone in reducing renal disease and prolonging survival of B/W mice with advanced nephritis. This striking reversal of proteinuria is unprecedented in animal models of SLE.
AB - Cyclophosphamide (CTX) prevents progression of nephritis and prolongs survival in (NZB x NZW)F1 (B/W) mice and is used to treat humans with lupus nephritis. To compare the efficacy of CTLA4Ig with CTX and determine whether there is an incremental benefit to combining CTLA4Ig with CTX, we treated B/W mice with CTX, CTLA4Ig, or both agents. In mice with mild renal disease, treatment delayed the onset of proteinuria and prolonged survival in all groups. In mice with advanced renal disease, treatment with both agents reduced proteinuria in 71% of mice, whereas mice treated with either agent alone had no such improvement. Survival was also markedly improved among mice treated with both agents. Thus, combination treatment with CTX and CTLA4Ig is more effective than either agent alone in reducing renal disease and prolonging survival of B/W mice with advanced nephritis. This striking reversal of proteinuria is unprecedented in animal models of SLE.
UR - http://www.scopus.com/inward/record.url?scp=0035284737&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035284737&partnerID=8YFLogxK
U2 - 10.4049/jimmunol.166.5.2913
DO - 10.4049/jimmunol.166.5.2913
M3 - Article
C2 - 11207238
AN - SCOPUS:0035284737
SN - 0022-1767
VL - 166
SP - 2913
EP - 2916
JO - Journal of Immunology
JF - Journal of Immunology
IS - 5
ER -